According to the findings of our clinical staging, RBP1 expression was higher in the intermediate and late stages of four malignancies, including BLCA and COAD, but was lower in the higher stages of BRCA, ESCA, and MESO tumors. This evidence concerns the gene RBP1 and bladder transitional cell carcinoma.